Remission (response plus end score 8 or less) · adults with seasonal affective disorder
It is very uncertain whether fluoxetine changes remission (response plus end score 8 or less) compared with light therapy (very low certainty).
1 finding from 1 review
Speed of onset of response · adults with seasonal affective disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events ‐ treatment emergent · adults with seasonal affective disorder
Fluoxetine showed no clear difference in adverse events (at least 1 treatment‐emergent adverse event) compared with light therapy (low certainty).
1 finding from 1 review
Response (> 50% improvement on 24‐item HAM‐D SIGH‐SAD) · adults with seasonal affective disorder
Fluoxetine showed no clear difference in response (> 50% improvement on 24‐item HAM‐D SIGH‐SAD) compared with light therapy (low certainty).
1 finding from 1 review
Clinical Global Impressions ‐ Improvement of condition (CGI‐I) Rating of 1 = very much improved to 7 = very much worse · adults with seasonal affective disorder
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life (SF‐20 & Q‐LES‐Q) Eight weeks · adults with seasonal affective disorder
1 finding from 1 review
Failure to respond (reduction ≥ 50% on HDRS) · patients with depression
Fluoxetine showed no clear difference in failure to respond (reduction ≥ 50% on HDRS) compared with TCAs (moderate certainty).
1 finding from 1 review
Failure to complete ‐ side effects ‐ · patients with depression
Fluoxetine may leads to lower failure to complete ‐ side effects ‐ compared with ABT‐200 (low certainty).
1 finding from 1 review
Failure to complete ‐ side effects ‐ · patients with depression
It is very uncertain whether fluoxetine changes failure to complete ‐ side effects ‐ compared with phenelzine (very low certainty).
1 finding from 1 review
Failure to respond (reduction ≥ 50% on HDRS) · patients with depression
Fluoxetine showed no clear difference in failure to respond (reduction ≥ 50% on HDRS) compared with pramipexole (low certainty).
1 finding from 1 review
Endpoint score (HDRS or MADRS) · patients with depression
1 finding from 1 review
Failure to complete ‐ total ‐ · patients with depression
Fluoxetine may leads to lower failure to complete ‐ total ‐ compared with pramipexole (low certainty).
1 finding from 1 review
Failure to complete ‐ inefficacy ‐ · patients with depression
Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with pramipexole (low certainty).
1 finding from 1 review
Failure to complete ‐ side effects ‐ · patients with depression
Fluoxetine may leads to lower failure to complete ‐ side effects ‐ compared with pramipexole (low certainty).
1 finding from 1 review
Failure to respond (reduction ≥ 50% on HDRS) · patients with depression
Fluoxetine showed no clear difference in failure to respond (reduction ≥ 50% on HDRS) compared with reboxetine (moderate certainty).
1 finding from 1 review
Endpoint score (HDRS or MADRS) · patients with depression
1 finding from 1 review
Failure to complete ‐ total ‐ · patients with depression
Fluoxetine probably leads to lower failure to complete ‐ total ‐ compared with reboxetine (moderate certainty).
1 finding from 1 review
Failure to complete ‐ inefficacy ‐ · patients with depression
Fluoxetine showed no clear difference in failure to complete ‐ inefficacy ‐ compared with reboxetine (moderate certainty).
1 finding from 1 review
Failure to respond (reduction ≥ 50% on HDRS) · patients with depression
Fluoxetine showed no clear difference in failure to respond (reduction ≥ 50% on HDRS) compared with agomelatine (low certainty).
1 finding from 1 review
Failure to complete ‐ side effects ‐ · patients with depression
Fluoxetine showed no clear difference in failure to complete ‐ side effects ‐ compared with reboxetine (moderate certainty).
1 finding from 1 review